Issac Grinberg, MD
Cardiovascular Disease · Southfield, MINPI 1790768257
Payments from drug & device makers
Across 184 payments — averaging $51.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Boston Scientific$812
- Medtronic$783
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$562
- Novartis$406
- Kestra Medical Technology Services, Inc.$321
- plus $1K from 20 others
What the payments were for
- Food & beverage$9,530100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 51 | $5,279 |
| Boston Scientific | 19 | $812 |
| Medtronic(2 entities) | 9 | $783 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $562 |
| Novartis | 30 | $406 |
| Kestra Medical Technology Services, Inc. | 4 | $321 |
| Johnson & Johnson | 16 | $209 |
| Amgen | 2 | $162 |
| Inari Medical, Inc. | 1 | $162 |
| E.r. Squibb & Sons, L.L.C. | 12 | $151 |
| Boehringer Ingelheim | 1 | $125 |
| Siemens Medical Solutions USA, Inc. | 3 | $112 |
| Chiesi USA, Inc. | 2 | $88 |
| Edwards Lifesciences | 4 | $68 |
| Novo Nordisk | 2 | $60 |
| Merck | 2 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Impulse Dynamics (USA) Inc. | 1 | $31 |
| Cordis US CORP. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Pfizer | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER AMULET$883
- ENSITE$460
- ENSITE PRECISION$412
- AMPLATZER Occluders$340
- CoreValve Evolut$337
- LifeVest$326
- CardioMEMS HF System$308
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$289
- AVEIR$239
- Fortify Assura, Ellipse ICD$222
- WATCHMAN Access System$172
- AGILIS$170
- FLOWTRIEVER CATHETER, S$162
- CT THROMBECTOMY SYSTEM KIT$162
- AMPLATZER$153
- Assure WCD$150
- GALLANT$149
- Accent Pacemaker$148
- Confirm Rx$144
- Unify Assura CRT Defibrillator$144
How this compares
$9,530 in reported general payments places this provider in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 292 | $360,853 |
| EntrestoSacubitril/Valsartan | 75 | $101,179 |
| XareltoRivaroxaban | 35 | $52,420 |
| Repatha SureclickEvolocumab | 32 | $43,582 |
| JardianceEmpagliflozin | 13 | $17,208 |
| Repatha PushtronexEvolocumab | 11 | $14,463 |
| BrilintaTicagrelor | 13 | $11,507 |
| Metoprolol Succinate | 590 | $9,968 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 180 | $8,376 |
| Atorvastatin Calcium | 537 | $7,803 |
| Olmesartan Medoxomil | 330 | $7,523 |
| Ranolazine ErRanolazine | 26 | $3,336 |
| Carvedilol | 268 | $3,299 |
| Ezetimibe | 139 | $2,972 |
| Amiodarone Hcl | 46 | $2,612 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $360,853292 claims |
| NovartisEntresto | $406 | $101,17975 claims |
| Johnson & JohnsonXarelto | $209 | $52,42035 claims |
| Boehringer IngelheimJardiance | $125 | $17,20813 claims |
| AstraZenecaBrilinta | $14 | $11,50713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Southfield
- Herman KadoSouthfield$766K
- Stanley ChetcutiAnn Arbor$4.3M
- Sandeep KhuranaGrandville$2.3M
- Victor MolesAnn Arbor$2.1M
- Jihad MustaphaGrand Rapids$1.9M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Brian OneillDetroit$1.4M
- Vallerie McLaughlinAnn Arbor$1.4M
- Ahmad MizyedYpsilanti$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.